Document Detail

The L.E.A.P.S. approach to vaccine development.
MedLine Citation:
PMID:  15569618     Owner:  NLM     Status:  MEDLINE    
The Ligand Epitope Antigen Presentation System (L.E.A.P.S.) approach to vaccine development utilizes immune peptides to promote the immunogenicity and influence the type of immune response generated towards epitopes in peptides which may be too small to elicit an immune response. The covalent attachment of these immune peptides to the antigenic peptide promotes the interaction of the epitope with T cells (T cell binding ligand (TCBL)) or antigen presenting cells (immune cell binding ligand (ICBL)) and ultimately promotes binding with the T cell receptor on CD4 or CD8 T cells. The, J, ICBL/TCBL peptide derived from the beta-2-microglobulin chain of MHC I molecules promotes Th1 type responses to the antigenic peptide while the, G, ICBL/TCBL peptide derived from the beta chain of MHC II molecules promotes Th2 types of responses. The efficacy of this approach has been demonstrated by characterization of the immune responses to L.E.A.P.S. vaccines and by elicitation of protection from infectious challenge with herpes simplex virus and other pathogens. The protection studies show that the L.E.A.P.S. approach allows customization of the immune response appropriate for inducing protection from disease. The theory, background, examples and studies of the mechanism of action of the L.E.A.P.S. vaccines will be discussed.
Daniel H Zimmerman; Ken S Rosenthal
Related Documents :
12697738 - Sensitizing antigen-specific cd8+ t cells for accelerated suicide causes immune incompe...
16978698 - Respiratory syncytial virus inhibits interferon-alpha-inducible signaling in macrophage...
17389578 - Rsv-infected airway epithelial cells cause biphasic up-regulation of ccr1 expression on...
7923138 - Murine immune response to cells transfected with human muc1: immunization with cellular...
19299708 - 4-1bb functions as a survival factor in dendritic cells.
17589288 - Enhancing antitumor immunity: combining il-12 with tgfbeta1 antagonism.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review     Date:  2005-01-01
Journal Detail:
Title:  Frontiers in bioscience : a journal and virtual library     Volume:  10     ISSN:  1093-4715     ISO Abbreviation:  Front. Biosci.     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2004-11-30     Completed Date:  2006-07-07     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9709506     Medline TA:  Front Biosci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  790-8     Citation Subset:  IM    
Cel-Sci Corporation, 8229 Boone Blvd, Suite 802, Vienna, VA 22182, USA. <>
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigen Presentation*
Drug Design*
Drug Industry / methods*
Epitopes / chemistry
HIV / metabolism
Immune System / metabolism*
Simplexvirus / metabolism
T-Lymphocytes / metabolism
Vaccines / therapeutic use*
Grant Support
1 R43 055069-01//PHS HHS; 1 R43HL 71352-01A1/HL/NHLBI NIH HHS; AI 43107-03/AI/NIAID NIH HHS; AI43 43107-01/AI/NIAID NIH HHS; U-01AI 054747-01/AI/NIAID NIH HHS
Reg. No./Substance:
0/Epitopes; 0/Vaccines

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Molecular aspects of vascular tissue engineering.
Next Document:  Absorption of myo-inositol hexakisphosphate (InsP6) through the skin: study of the matrix effects. m...